GH Form 4: Director Manuel Hidalgo Medina reports 232-share RSU vesting

Rhea-AI Filing Summary

Insider reported acquisition of shares from restricted stock units. Manuel Hidalgo Medina, a director of Guardant Health, acquired 232 shares on 08/17/2025 at a reported price of $0, increasing his direct common stock holdings to 3,016 shares. The filing also reports the conversion/vesting of 232 restricted stock units on the same date, leaving 8,121 restricted stock units (reported as derivative securities) beneficially owned in a direct capacity. The RSU award was granted on July 17, 2024 and vests over four years, with 25% vesting at the one-year anniversary and the remaining 75% vesting monthly over the next three years. The form was signed via attorney-in-fact on 08/18/2025.

Positive

• 232 restricted stock units vested and converted to common stock on 08/17/2025, increasing direct holdings.
• Clear vesting schedule disclosed: grant date July 17, 2024 with four-year vesting (25% at one year, remainder monthly).
• Post-transaction holdings reported: 3,016 shares directly and 8,121 RSU-related derivative interests directly beneficially owned.

Negative

• None.

Insights

Securities Analyst

TL;DR: Director received vested RSUs converting to 232 shares, modestly increasing direct ownership.

The Form 4 documents a standard vesting event rather than an open-market purchase or sale. The reported 232 shares were acquired with a stated price of $0, consistent with conversion of restricted stock units into common shares. Post-transaction, the reporting person holds 3,016 common shares directly and 8,121 RSU-related derivative interests reported as direct beneficial ownership. This is a routine equity compensation disclosure for a director and appears immaterial to capitalization or control.

Corporate Governance Specialist

TL;DR: Transaction reflects scheduled RSU vesting tied to a 2024 grant, not an unusual insider action.

The filing explicitly notes the RSU grant date of July 17, 2024 and the four-year vesting schedule (25% after one year, remainder monthly over three years). The conversion/vesting on 08/17/2025 aligns with that schedule. The use of an attorney-in-fact signature is documented. From a governance perspective, this is a routine disclosure of compensation-related vesting rather than a signal of non-routine insider trading.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hidalgo Medina Manuel

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2025		M		232	A	$0	3,016	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	08/17/2025		M			232	(1)	(2)	Common Stock	232	$0	8,121	D

Explanation of Responses:

1. The restricted stock unit granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of July 17, 2024 and the remaining 75% vests monthly for the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Manuel Hidalgo Medina report on Form 4 for GH?

The filing reports the acquisition of 232 shares on 08/17/2025 at a reported price of $0, reflecting vesting/conversion of restricted stock units.

How many shares does Manuel Hidalgo Medina own after the reported transaction?

The Form 4 shows 3,016 common shares beneficially owned directly following the reported transaction.

How many restricted stock units or derivative interests are reported?

The filing reports 8,121 restricted stock units/derivative securities reported as directly beneficially owned after the transaction.

When was the RSU grant and what is the vesting schedule?

The RSU grant was on July 17, 2024. It vests over four years: 25% vested at the one-year anniversary and the remaining 75% vests monthly over the following three years.

Who signed the Form 4 filing for Manuel Hidalgo Medina?

The Form 4 was signed by John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina on 08/18/2025.